[{"AccountsPayableCurrent_0_Q1_USD":2426000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":640000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":2566000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":3462000.0,"OtherLiabilitiesCurrent_0_Q1_USD":1408000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-1750000.0,"IncreaseDecreaseInContractWithCustomerAsset_1_Q1_USD":212000.0,"ContractWithCustomerAssetNetCurrent_0_Q1_USD":344000.0,"PaymentsToAcquireInvestments_1_Q1_USD":8885000.0,"IncreaseDecreaseInOtherCurrentLiabilities_1_Q1_USD":0.0,"WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_1_Q1_shares":1670606.0,"IncomeLossFromEquityMethodInvestments_1_Q1_USD":-482000.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q1_USD":157578000.0,"AvailableForSaleSecurities_0_Q1_USD":157866000.0,"AvailableForSaleSecuritiesCurrent_0_Q1_USD":90540000.0,"DeferredRentCreditNoncurrent_0_Q1_USD":3590000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q1_USD":224000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":224000.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q1_USD":-0.63,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-27529000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":483000.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_1_Q1_USD":0.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":648000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":248000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":315000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1_Q1_USD":0.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_1_Q1_USD":49150000.0,"IncreaseDecreaseInOtherNoncurrentAssets_1_Q1_USD":91000.0,"IncreaseDecreaseInDueFromRelatedPartiesCurrent_1_Q1_USD":0.0,"GainLossOnSaleOfEquityInvestments_1_Q1_USD":482000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1_Q1_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_1_Q1_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_1_Q1_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_1_Q1_USD":0.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":3462000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"DeferredRevenueRevenueRecognized1_1_Q1_USD":1750000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":10272000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":7000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":9389000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":67529000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q1_USD":67326000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":27000.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"RestrictedCashNoncurrent_0_Q1_USD":203000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":45953213.0,"NonoperatingIncomeExpense_1_Q1_USD":647000.0,"NetIncomeLoss_1_Q1_USD":-27753000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-31277000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":40056000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":610000.0,"LiabilitiesCurrent_0_Q1_USD":21004000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":176144000.0,"Liabilities_0_Q1_USD":35506000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":3704000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":-2342000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":209000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":7008000.0,"CommonStockValue_0_Q1_USD":4000.0,"CommonStockSharesOutstanding_0_Q1_shares":45982788.0,"CommonStockSharesIssued_0_Q1_shares":45982788.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":67326000.0,"AssetsCurrent_0_Q1_USD":166217000.0,"Assets_0_Q1_USD":176144000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":8359101.0,"AdditionalPaidInCapital_0_Q1_USD":373425000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":288000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.63,"OtherAssetsNoncurrent_0_Q1_USD":963000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":8007000.0,"ProfitLoss_1_Q1_USD":-27753000.0,"CapitalExpendituresIncurredButNotYetPaid_1_Q1_USD":76000.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":323000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":643000.0,"ShareBasedCompensation_1_Q1_USD":3462000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":23142000.0,"PreferredStockValue_0_Q1_USD":0.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PreferredStockSharesAuthorized_0_Q1_shares":10000000.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":643000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"OperatingExpenses_1_Q1_USD":30150000.0,"DepreciationAndAmortization_1_Q1_USD":842000.0,"CommonStockSharesAuthorized_0_Q1_shares":400000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"AccruedLiabilitiesCurrent_0_Q1_USD":10170000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":44282607.0,"StockholdersEquity_0_Q1_USD":140638000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-233079000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":8761000.0,"OperatingIncomeLoss_1_Q1_USD":-28400000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":1750000.0,"Ticker":"RCUS","CIK":"1724521","name":"ARCUS BIOSCIENCES, INC.","OfficialName":"Arcus Biosciences Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2226368293.0","Country":"nan","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20200505"}]